Wedbush reiterated an Outperform rating and $16 price target on Rocket Pharmaceuticals (RCKT), saying the Kresladi approval is a “significant milestone” for the company, which the firm believes reflects management’s strong execution. Payer coverage should not be an issue, and the priority review voucher will strengthen Rocket’s balance sheet, the analyst tells investors in a research note. The firm added that it does not see the negative stock price reaction as justified.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Rocket Pharmaceuticals: FDA Validation, Non-Dilutive Funding Catalyst, and Pipeline De-Risking Support Buy Rating
- Rocket Pharmaceuticals: Kresladi Approval, Non‑Dilutive Capital, and Danon Pipeline Progress Underscore Buy Rating Despite Share Weakness
- Rocket Pharmaceuticals: First Approval and Extended Cash Runway Offset by Long Path to Meaningful Kresladi Revenues, Warranting a Hold Rating
- Video: Unity rises after better-than-expected pre-announcement
- Rocket Pharmaceuticals wins FDA nod for KRESLADI gene therapy